Core Viewpoint - Anteris Technologies has secured a $90 million strategic investment from Medtronic, which follows a $320 million underwritten offering of common stock, aimed at advancing the global pivotal PARADIGM trial and commercializing the DurAVR® Transcatheter Heart Valve [1][3]. Group 1: Investment and Collaboration - The investment from Medtronic is seen as a significant milestone for Anteris, validating its program in the capital markets and indicating potential future collaborations [3]. - Anteris and Medtronic share a vision of advancing the Transcatheter Aortic Valve Replacement (TAVR) market through improved clinical science and valve design, focusing on durability and long-term patient outcomes [2][3]. Group 2: PARADIGM Trial - The PARADIGM Trial is a randomized controlled trial designed to evaluate the safety and effectiveness of the DurAVR® THV against existing TAVR options, with an enrollment target of approximately 1,000 patients [4][5]. - The trial will assess non-inferiority based on a primary composite endpoint that includes all-cause mortality, all strokes, and cardiovascular hospitalizations at one year post-procedure [5]. - Recruitment for the PARADIGM Trial has already begun, with the first patients enrolled in the fourth quarter of 2025 [6]. Group 3: Product Overview - Anteris' lead product, the DurAVR® Transcatheter Heart Valve, is designed to treat aortic stenosis and is the first biomimetic valve, aiming to replicate the performance of a healthy aortic valve [8]. - The DurAVR® THV is constructed from Anteris' patented ADAPT® tissue technology, which has been clinically used for over 10 years and is FDA-cleared, having been distributed to over 55,000 patients globally [8].

MINNEAPOLIS and BRISBANE, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the closing of its underwritten public offering (the “Offering”) of 40,000,000 shares of its common stock, including the exercise in full of the underwriters’ option to purchase addit ...

Core Viewpoint - Anteris Technologies Global Corp. has announced a public offering of 34,782,609 shares at a price of $5.75 per share, aiming to raise approximately $200 million to support its growth and clinical strategy [1][4]. Group 1: Offering Details - The public offering consists of 34,782,609 shares priced at $5.75 each, with expected gross proceeds of around $200 million before expenses [1]. - The underwriters have a 30-day option to purchase an additional 5,217,391 shares at the public offering price [2]. - The offering is set to close on January 22, 2026, pending customary closing conditions [1]. Group 2: Private Placement - Anteris has agreed to sell up to $90 million of shares to Medtronic plc in a private placement, with a minimum purchase of 16% and a maximum of 19.99% of the shares outstanding after the offering [3]. - The completion of the private placement is contingent on the successful completion of the public offering [3]. Group 3: Use of Proceeds - The net proceeds from the offering and private placement will be used to advance the clinical strategy, including the DurAVR® THV global pivotal trial for severe aortic stenosis [4]. - Additional funds will support the expansion of manufacturing capabilities and ongoing research and development for v2vmedtech, inc., with remaining funds allocated to working capital and general corporate purposes [4]. Group 4: Company Overview - Anteris Technologies is a global structural heart company focused on developing innovative medical devices to restore heart function [10]. - The lead product, DurAVR® THV, is designed to treat aortic stenosis and is made from Anteris' patented ADAPT® tissue technology, which has been used in over 55,000 patients worldwide [11].

ANTERIS TECHNOLOGIES GLOBAL CORP. (Exact name of registrant as specified in its charter) TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 26, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3842 99-1407174 (I.R.S. Employer Identific ...

Core Points - Anteris Technologies Global Corp. has adjourned its Special Meeting of Stockholders due to lack of quorum, rescheduling it for September 29, 2025 [1][2] - The Company encourages stockholders to vote on proposals outlined in the definitive Proxy Statement filed with the SEC on August 18, 2025 [2][6] - Anteris is focused on developing innovative medical devices for heart function restoration, with its lead product being the DurAVR® Transcatheter Heart Valve [7][8] Voting Details - Stockholders who have already voted do not need to take further action as their votes will remain counted [3] - New votes can be submitted via the Proxy Statement, with deadlines for Internet and telephone submissions set for September 28, 2025, and for mail submissions by September 26, 2025 [4] - CDI holders must direct CDN to vote by September 25, 2025, to ensure their votes are counted [5] Company Overview - Anteris Technologies is a global structural heart company with a significant presence in both Australia and the USA [7] - The DurAVR® Transcatheter Heart Valve is designed to treat aortic stenosis and is the first biomimetic valve, utilizing Anteris' patented ADAPT® tissue technology [8]